Plectonic Logibody GmbH

Plectonic Logibody GmbH is a biotechnology company developing LOGIBODY®, a programmable DNA-protein therapeutic platform for precision cancer immunotherapy. Its molecular logic gates selectively direct immune responses toward tumor cells, while multispecific T-cell-engaging biologics aim to reduce off-target toxicity and improve treatment impact. The company conducts research with Plectonic Biotech and is advancing DNA-based therapies from preclinical studies toward clinical trials.